A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)

被引:10
|
作者
Liu, Xuechao [1 ,2 ,3 ]
Qiu, Haibo [1 ,2 ,3 ]
Wu, Zhiming [1 ,2 ,4 ]
Zhang, Peng [5 ]
Feng, Xingyu [6 ]
Chen, Tao [7 ]
Li, Yong [6 ]
Tao, Kaixiong [5 ]
Li, Guoxin [7 ]
Sun, Xiaowei [1 ,2 ,3 ]
Zhou, Zhiwei [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 East Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Dept Urol, Guangzhou, Guangdong, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Hubei, Peoples R China
[6] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[7] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
基金
美国国家科学基金会;
关键词
Gastrointestinal stromal tumor; Pathological prognostic score; Ki-67 labeling index; Mitotic index; Prognosis; ADJUVANT IMATINIB MESYLATE; KI-67; THERAPY; KIT; MANAGEMENT; MUTATIONS; DIAGNOSIS; SURVIVAL; IMPACT; TRIAL;
D O I
10.1007/s11605-018-3799-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients. Methods We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015. Results Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index >= 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309-5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05). Conclusion The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.
引用
收藏
页码:2150 / 2157
页数:8
相关论文
共 50 条
  • [41] Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
    Hoon, Dave S. B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (02): : 74 - 75
  • [42] Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients
    Zhao, Ying
    Wang, Hong
    Jin, Song
    Zheng, Jiajia
    Huang, Man
    Tang, Yaqiong
    Jin, Zhengming
    Qiu, Huiying
    Tang, Xiaowen
    Fu, Chengcheng
    Han, Yue
    Wu, De-Pei
    ONCOTARGET, 2017, 8 (42) : 73168 - 73176
  • [43] Transfer in ICU of febrile neutropenic patients: prospective validation of a prognostic score identifying 'high-risk' patients
    J Larché
    F Alla
    P Maurer
    O Kunzberger
    A Gérard
    Critical Care, 7 (Suppl 2):
  • [44] Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study
    Kim, Kihyun
    Kim, Jin Seok
    Yoon, Sung-Soo
    Yoon, Dok-Hyun
    Eom, HyeonSeok
    Lee, Je-Jung
    Yim, Hyeonwoo
    Park, Misun
    Lee, Hojoon
    Min, Chang Ki
    BLOOD, 2020, 136
  • [45] ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?
    Toto Hølmebakk
    Kjetil Boye
    Annals of Surgical Oncology, 2021, 28 : 6846 - 6847
  • [46] The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).
    Rutkowski, Piotr
    Zietek, Marcin
    Cybulska-Stopa, Bozena
    Streb, Joanna
    Gluszek, Stanislaw
    Jankowski, Michal
    Lopacka-Szatan, Karolina
    Las-Jankowska, Manuela
    Hudziec, Piotr
    Klimczak, Anna
    Olesinski, Tomasz
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Bylina, Elzbieta
    Osuch, Czeslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Tumor budding as an index to identify high-risk patients with stage II colon cancer
    Nakamura, Takatoshi
    Mitomi, Hiroyuki
    Kanazawa, Hideki
    Ohkura, Yasuo
    Watanabe, Masahiko
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 568 - 572
  • [48] THE CLINICAL SYNTAX SCORE IS SUPERIOR TO THE SYNTAX SCORE IN HIGH-RISK PATIENTS
    Kang, Jeehoon
    Park, Kyung Woo
    Han, Jung-Kyu
    Yang, Han-Mo
    Kang, Hyun-Jae
    Koo, Bon Kwon
    Kim, Hyo-Soo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 171 - 171
  • [49] Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors
    Li, Yan-Shu
    Li, Wei
    Zeng, Qing-Sheng
    Fu, Wei-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 4713 - 4719
  • [50] Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib
    Bang, Yeong Hak
    Ryu, Min-Hee
    Kim, Hyung-Don
    Lee, Hyung Eun
    Kang, Yoon-Koo
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (10) : 1770 - 1777